Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term propranolol therapy for angina pectoris

S G Warren, D L Brewer, E S Orgain

    The American Journal of Cardiology
    |March 4, 1976
    PubMed
    Summary

    Propranolol effectively treats severe angina pectoris long-term, reducing mortality in patients with significant symptom relief. However, it may increase risks for heart failure and cardiogenic shock in specific patient groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The practical use of digitals.

    North Carolina medical journal·2010
    Same author

    The cardiac glycosides.

    North Carolina medical journal·2010
    Same author

    Treatment of the cardiac arrhythmias.

    North Carolina medical journal·2010
    Same author

    Recent advances in the treatment of cardiovascular disease.

    North Carolina medical journal·2010
    Same author

    The treatment of congestive heart failure.

    North Carolina medical journal·2010
    Same author

    AUGMENTATION OF THE EXTRACARDIAC ANASTOMOSES OF THE CORONARY ARTERIES THROUGH PERICARDIAL ADHESIONS.

    The Journal of experimental medicine·2009

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Severe angina pectoris (New York Heart Association functional class III or IV) requires effective long-term management.
    • Propranolol is a beta-blocker used for cardiovascular conditions.

    Purpose of the Study:

    • To assess the long-term effectiveness and complication rate of propranolol in patients with severe angina.
    • To evaluate the impact of propranolol on mortality and adverse events over a 5 to 8-year follow-up period.

    Main Methods:

    • Prospective study of 63 patients with stable, severe typical angina pectoris treated with propranolol.
    • Follow-up period of 5 to 8 years, monitoring mortality, angina reduction, heart failure, and side effects.

    Main Results:

    • Average yearly mortality rate was 3.8%; cumulative 5-year mortality was 19%.
    • A 50% or greater reduction in angina predicted a significantly lower mortality rate (P < 0.01).
    • Heart failure developed in 25% of patients; risk factors included prior congestive heart failure and cardiothoracic ratio > 0.5.

    Conclusions:

    • Propranolol is an effective long-term therapy for severe angina, without inducing tachyphylaxis or increasing overall mortality.
    • Significant reduction in anginal pain with propranolol is a positive prognostic indicator.
    • History of congestive heart failure, cardiothoracic ratio > 0.5, and mild asthma are relative contraindications for propranolol therapy.

    Related Experiment Videos